Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + Dalpiciclib + Endocrine Therapy in HR+/HER2- Breast Cancer
NCT06599216Phase 2Active, not recruiting
- Sponsor
- Harbin Medical University
- Start
- Oct 2024
- Primary completion
- Mar 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab in breast cancer, sponsored by Harbin Medical University. Started Oct 2024; status: active, not recruiting.
02
Drugs
adebrelimab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06599216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06599216.